Results 81 to 90 of about 4,251 (181)

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

The Journal of Clinical Investigation, 2023
BACKGROUND IgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies.
Ragha V. Suresh, Collin Dunnam, Dhananjay Vaidya, Robert A. Wood, Bruce S. Bochner, Donald W. MacGlashan Jr., Melanie C. Dispenza   +6 more
doaj   +1 more source

Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr-/- mice

, 2023
Atherosclerosis is characterized by the accumulation of lipids and immune cells, including mast cells and B cells, in the arterial wall. Mast cells contribute to atherosclerotic plaque growth and destabilization upon active degranulation.
Mireia N.A. Bernabé Kleijn, Kuiper, J., Johan Kuiper, Danique Biskop, Amanda C. Foks, Depuydt, M.A.C., Lucie Delfos, Ilze Bot, Marie A.C. Depuydt, Hemme, E.: Biskop, D., Virginia Smit, Delfos, L., Bernabé Kleijn, M.N.A., Foks, A.C., Bot, I., Smit, V., Esmeralda Hemme   +16 more
core   +1 more source

Supplemental figures from Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

, 2017
Figure 1. Structures of acalabrutinib and ibrutinib. A. Chemical structure of acalabrutinib. B. Chemical structure of ibrutinib.
Mary Ayres (356964), William G. Wierda (12115368), Viralkumar Patel (15007709), Kumudha Balakrishnan (1322475), Michael J. Keating (7585280), Varsha Gandhi (147452), Elena Bibikova (71101)   +6 more
core   +1 more source

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis

Experimental Hematology & Oncology
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown.
Joachim Alexandre, Jonaz Font, Thibault Lenormand, Sylvain Chantepie, Hippolyte Bardet, Gandhi Damaj, Charles Dolladille, Damien Legallois, Angélique Da-Silva, Paul Milliez, Arnaud Bisson, Laurent Fauchier   +11 more
doaj   +1 more source

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN after a median follow-up of 74.5 months. Overall, 535 patients were randomized (acalabrutinib-obinutuzumab,
Munir, Talha, Kamdar, Manali, Flinn, Ian W., Banerji, Versha, Byrd, John C, Suterwala, Batul T., Hughes, Marie, Munugalavadla, Veerendra, Wun, Chuan-Chuan, Herishanu, Yair, Woyach, Jennifer A., Jurczak, Wojciech, Patel, Krish, Fogliatto, Laura Maria, Woyach, Jennifer A, Ferrant, Emmanuelle, Janssens, Ann, Sharman, Jeff P., Flinn, Ian W, Walker, Patricia, Ferrajoli, Alessandra, Skarbnik, Alan, Follows, George, Miranda, Paulo, Wierda, William G, Sharman, Jeff P, Walewska, Renata, Suterwala, Batul T, Byrd, John C., Wierda, William G., Egyed, Miklos, Ghia, Paolo, Wachira, Catherine Wangui   +32 more
core   +1 more source

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia

Journal of Comparative Effectiveness Research
Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) from a Medicare perspective.
Adam S Kittai, Dipen A Patel, Jason Shafrin, Nadine Zawadzki, Vikram S Shetty, Yazan K Barqawi, Joanna M Rhodes   +6 more
doaj   +1 more source

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

Cardio-Oncology
Background First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of ...
Srilakshmi Vallabhaneni, Srinath Adusumalli, Jingyi Wu, Peter W. Groeneveld, James Gerson, Rupal P. O’Quinn   +5 more
doaj   +1 more source

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

, 2020
Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) often have a poor prognosis despite therapies using second-line chemoimmunotherapy. Achievement of CR with second-line therapy is associated with improved long-term
Fesler, Joanna, Hegerova, Livia, Batchelder, Ami, Pagel, John M, Egan, Daniel N, Bensinger, William, Holdread, Heather, Patel, Krish, Bailey, Megumi, Szeto, Jennie, Tsomo, Tenzin, Glennie, Sonia, Bailey, Neil, Mawad, Raya, Hall, Judson, Ferry, Joseph, Kane, David   +16 more
core  

Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial

healthbook TIMES. Oncology Hematology
Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis.
Adrian Schmidt
doaj   +1 more source

Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk

Acta Haematologica Polonica
Acalabrutinib belongs to a class of Bruton’s tyrosine kinase inhibitors (BTKis) which have become one of the most widely used drugs for the treatment of B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...
Anna Ewa Wolska-Washer, Tadeusz Robak
doaj   +1 more source